@Jonathan Edwards, here is my understanding of your position: There may be a subset of ME patients whose underlying pathology is some sort of auto-immune disease, and if so, this auto-immunity almost certainly wasn't triggered by an infection. Is that a fair characterization?
I find this hard to square with what we saw in the phase 2 open-label Rituximab trial. 7 of the 28 patients went into long-term remission after just 5-6 infusions. Because their remission was long-term, it seems like they must have an auto-immune disease and Rituximab broke the feedback loop. (I believe you have previously said that long-term remission from Rituximab is evidence that the underlying disease in the treated patient is auto-immune.) For 4 of those 7 patients, their ME began with a viral infection (specifically mono, or glandular fever, in 3 of them). It seems to me that a viral infection must have triggered an auto-immune disease in these people.
That's not to say the infection was the sole cause of these people developing auto-immune disease. I'm sure there's also a randomness element, and maybe also a genetic factor. But the above seems to indicate that in some ME patients, the underlying pathology is an auto-immune disease that's triggered by an infection.
Your thoughts?